Artiva Biotherapeutics discontinues AlloNK after insufficient response durability and two deaths, including fatal leukoencephalopathy linked to fludarabine neurotoxicity.
Written By: Sravani Pamanji, PharmD
Reviewed By: Pharmacally Editorial Team
On October 27, 2026, Artiva Biotherapeutics announced that it would discontinue development of AlloNK® (AB-101), its investigational allogeneic natural killer (NK) cell therapy. The programme evaluated AlloNK with rituximab in rheumatoid arthritis (RA) and other B-cell-driven autoimmune diseases. The decision followed an assessment of updated clinical findings, response durability, safety events, and the programme’s overall development prospects.
Artiva said the updated data continued to show deep B-cell depletion and clinical activity, consistent with earlier disclosures. However, responses did not demonstrate the durability required to justify further development. The company also reported two deaths among programme participants, including one fatal neurological event assessed as likely related to fludarabine-associated neurotoxicity. Artiva will not initiate its planned Phase 3 trial and has stopped dosing participants in ongoing AlloNK studies.
About AlloNK and Its Development Programme
AlloNK is a cryopreserved, non-genetically modified, allogeneic NK-cell therapy designed to enhance antibody-dependent cellular cytotoxicity when administered with therapeutic monoclonal antibodies such as rituximab, which targets CD20 on B cells. The combination was intended to achieve deep B-cell depletion in patients with autoimmune diseases driven by B-cell activity.
Artiva evaluated the combination in refractory RA, Sjögren disease, systemic sclerosis and other autoimmune indications, including myositis. The RA programme focused on patients with substantial unmet medical needs, including those who had responded inadequately to multiple advanced therapies.
In its September 8, 2026, update, Artiva planned to report additional Phase 2a findings and initiate a Phase 3 registrational trial in refractory RA during the second half of 2026. The proposed Phase 3 study was expected to enrol approximately 150 patients and compare AlloNK plus rituximab with rituximab alone. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 50% improvement response (ACR50) at six months. These plans have now been withdrawn.
Clinical Activity Did Not Translate into Sufficient Durability
Artiva said the updated findings continued to demonstrate deep B-cell depletion and clinical activity, but longer-term follow-up did not establish the response durability needed to support continued development.
The September update had outlined planned Phase 2a data disclosures from patients with refractory RA, Sjögren disease and systemic sclerosis, with specified minimum cohort sizes and at least six months of follow-up. These were planned disclosures rather than results from a completed Phase 3 study.
The October announcement did not provide detailed numerical results for response rates, duration of response or individual disease cohorts. Artiva also cancelled its planned presentation of the previously announced data at ACR Convergence 2026 and its November 9 investor webcast. Further disclosures may depend on the company’s strategic review.
The absence of detailed results limits independent assessment of the magnitude and durability of clinical benefit. Although B-cell depletion provides evidence of biological activity, it does not by itself establish sustained improvement in disease activity or long-term clinical benefit.
Two Deaths and the Regulatory Response
Artiva reported two deaths among participants in the programme.
The first occurred in the Phase 2a basket trial. A participant developed fatal leukoencephalopathy after receiving study treatment that included protocol-specified lymphodepletion with cyclophosphamide and fludarabine. Both the investigator and an independent safety review assessed the event as likely related to fludarabine-associated neurotoxicity.
Following notification of the event, the US Food and Drug Administration (FDA) asked Artiva to pause enrolment and dosing in the Phase 2a study. Artiva also paused activities related to enrolment and dosing in the planned Phase 3 trial. The company reported the event to the FDA, investigators and the Data Safety Monitoring Board and said it intended to publish further details.
The second death was sudden and occurred approximately two months after the participant began study treatment. The investigator assessed the event as unrelated to AlloNK or other components of the treatment regimen. The announcement did not disclose the cause of death.
Artiva subsequently decided to discontinue the programme and said no further participants would receive AlloNK in ongoing studies. It will work with the FDA, investigators and institutional review boards on study close-out, safety monitoring and required reporting.
Corporate Restructuring
The discontinuation reverses Artiva’s September plans to advance AlloNK into Phase 3. The company cited response durability, the overall benefit-risk assessment, anticipated enrolment delays, and development and commercial considerations.
Artiva is also reducing its workforce by approximately 94% while evaluating strategic alternatives, including a merger, business combination, asset sale or licensing, or dissolution and liquidation. It has engaged Leerink Partners as financial adviser. As of September 30, 2026, the company reported preliminary, unaudited cash, cash equivalents and investments of approximately $319.1 million, subject to adjustment.
Clinical Implications
AlloNK’s discontinuation highlights the distinction between demonstrating biological activity and establishing durable clinical benefit. The updated findings retained evidence of B-cell depletion and clinical activity, but the company concluded that the durability of responses did not justify progression to Phase 3.
The two deaths require separate interpretation. The first was assessed as likely related to fludarabine-associated neurotoxicity, while the second was judged unrelated to study treatment. The available disclosures do not establish that AlloNK itself caused both events. Without detailed efficacy results and comprehensive safety analyses, firm conclusions about the therapy’s efficacy and overall safety in individual indications remain premature.
References
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®, Artiva Biotherapeutics, October 27, 2026.
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026. Artiva Biotherapeutics, September 8, 2026.
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination with Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases, ClinicalTrials.gov ID NCT06991114
About the Writer
Sravani Pamanji is a PharmD (LinkedIn) professional with experience in scientific writing, medical literature review, drug profile preparation, and clinical case documentation. She has contributed to scientific publication and presented at the 74th Indian Pharmaceutical Congress. Her training includes ICH GCP E6(R3), scientific research, and medication safety. She is passionate about evidence-based medical communication and accurate dissemination of clinical and pharmaceutical information.